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Introduction
The production of antibodies using recombinant DNA 
technologies for therapy and prophylaxis in humans has 
blossomed in the last decade, opening the door to its use in 
the control of infectious diseases in animals. With such goal 
in mind, it becomes important to test the feasibility of this 
technology in the production of recombinant antibodies from 
animals of economic importance.
Porcine reproductive and respiratory syndrome (PRRS) 
is the most important infectious disease in swine, producing 
losses higher than 600 million dollars per year to the indus-
try.1 Porcine reproductive and respiratory syndrome virus 
(PRRSV) is the etiological agent of PRRS. Currently, attenu-
ated vaccines are in use to attempt protecting against PRRSV 
infection. Such protection is more successful in case of infec-
tion with PRRSV strains homologous to the vaccine strain, 
but not as efficient in the case of heterologous strains. There-
fore, the high heterogeneity of PRRSV field isolates makes it 
difficult to control this virus with the current vaccines.2, 3 In 
fact, protective vaccines or immunization regimes inducing 
the appearance of PRRSV-neutralizing antibodies against the 
homologous strain are associated with protection.4, 5 The role 
of neutralizing antibodies in protection of pregnant sows 
from abortion6 and piglets from viremia, viral spread, and 
shedding7 by passive transfer of immunoglobulins enriched 
in neutralizing antibody activity has been shown previ-
ously by us. These results suggest that neutralizing antibod-
ies could be used as immunoprophylactic pharmaceuticals 
against PRRS virus infection.
The use of monoclonal antibodies against infectious dis-
eases has been envisioned since the development of this tech-
nology.8, 9 However, it took almost 20 years until a commer-
cial product of this sort was available to intervene in human 
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Abstract
The development of hybridoma and recombinant DNA technologies has made it possible to use antibodies against cancer, au-
toimmune disorders, and infectious diseases in humans. These advances in therapy, as well as immunoprophylaxis, could also 
make it possible to use these technologies in agricultural species of economic importance such as pigs. Porcine reproductive and 
respiratory syndrome virus (PRRSV) is an arterivirus causing very important economic losses to the industry. Passive transfer 
of antibodies obtained by biotechnology could be used in the future to complement or replace vaccination against this and other 
pig pathogens. To this end, we constructed and studied the properties of chimeric mouse × pig anti-PRRSV antibodies. We 
cloned the constant regions of gamma-1 and gamma-2 heavy chains and the lambda light chain of pig antibodies in frame with 
the variable regions of heavy and light chains of mouse monoclonal antibody ISU25C1, which has neutralizing activity against 
PRRSV. The coding regions for chimeric IgG1 and IgG2 were expressed in a baculovirus expression system. Both chimeric anti-
bodies recognized PRRSV in ELISA as well as in a Western-blot format and, more importantly, were able to neutralize PRRSV 
in the same fashion as the parent mouse monoclonal antibody ISU25C1. In addition, we show that both pig IgG1 and IgG2 anti-
bodies could bind complement component C1q, with IgG2 being more efficient than IgG1 in binding C1q. Expressing chimeric 
pig antibodies with protective capabilities offers a new alternative strategy for infectious disease control in domestic pigs. 
Keywords: pig chimeric antibodies, PRRSV, baculovirus
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infections.10 One of the main problems of this approach has 
been the immune response of the nonmurine host against 
mouse monoclonal antibodies. This problem was first over-
come by using mouse × human chimeric antibodies and later 
by “humanizing” mouse monoclonal antibodies (reviewed 
in Reference 11). For example, humanized monoclonal neu-
tralizing antibody Palivizumab (Synagis®) directed against 
the F protein of respiratory syncitial virus (RSV) was the 
first antibody used against infectious diseases, which has 
proven successful in preventing infection of infants at risk.12 
Currently, many antibodies obtained by recombinant DNA 
technology are available in human medicine against cancer, 
autoimmune, and infectious diseases. The knowledge ac-
cumulated about mouse and human antibodies’ sequence, 
structure, and function of the different domains of the mol-
ecule has been important in the design and development of 
this new kind of prophylactic and therapeutic biologics.
Herein we show that it is feasible to produce mouse × 
pig chimeric antibodies in a baculovirus expression system 
that maintains the same properties of the Fv from mouse an-
tibodies. We also show the ability of the Fcs of pig IgGs to 
bind C1q of complement. Such preservation of the properties 
of the mouse × pig chimeric antibodies allow for a new pos-
sible strategy against PRRSV in pigs to provide immediate 
prevention of infection.
Materials and Methods
Cloning of constant regions of porcine lambda, gamma-1 and 
gamma-2 chains
Sequences encoding porcine heavy and light chain con-
stant regions were amplified from RNA, using primers 
based on the published sequences for gamma and lambda 
chains.13, 14 Standard cloning procedures were carried out.15 
Briefly, total RNA was isolated with TRIZOLTM (Gibco-In-
vitrogen, CA, USA) from spleen obtained by necropsy of a 
healthy, 4-month-old large-white pig. Reverse transcrip-
tion reactions were performed using SuperScriptTM (Invitro-
gen, CA, USA) for 50 min at 42°C and primers for porcine 
gamma-1 and gamma-2 (5′-TATGTACACAGCGCTGGGGC-
3′) and for porcine lambda chain (Oligo-dT). PCR were per-
formed using Pfu DNA Polymerase (Stratagene, CA, USA) in 
the manufacturer’s buffer using forward 1-19 Nhe I (5′-GC-
TAGCGCCCCCAAGACGGCCCCAT-3′) and reverse 977-999 
Kpn I (5′-GGTACCGCAGCGGGTGGCTCATTTACCCT-3′) 
primers for porcine gamma-1, forward 1-19 Kpn I (5′-GC-
TAGCGCCCCCAAGACGGCCCCAT-3′) and reverse 969-
988 Kpn I (5′-GGTACCTCATTTACCCGGAGTCTTG-3′) for 
porcine gamma-2, and forward 19-42 Hpa I (5′-ACTGTTA-
ACCTCTTCCCGCCCTCC-3′) and reverse 301-318 Bgl II 
(5′-AGATCTCTAGGCGCACTCGGAGGG-3′) for lambda 
constant chains. Recognition sites for the restriction endo-
nucleases are shown in italic font. The three DNA fragments 
were cloned in pGEM®-T Easy Vector (Promega, WI, USA).
Cloning of variable regions of murine lambda and gamma-1 chains
Heavy and light chain variable regions were amplified 
from hybridoma ISU25C1.16 ISU25C1 monoclonal antibod-
ies use gamma-1 and lambda chains and recognize an epi-
tope located at the ectodomain of glycoprotein GP5 from 
PRRSV strain KY35 (NVLS 46907). Mouse heavy chain vari-
able region was amplified by RACE-PCR (5′ RACE System 
for Rapid Amplification of cDNA Ends, Version 2.0; Invitro-
gen) from total RNA. cDNA was synthesized using a primer 
annealing between nucleotides 82 and 99 of the mouse an-
tibody gamma-1 chain (5′-GAAATAGCCCTTGACCAG-3′). 
PCR amplification of dC-tailed cDNA was performed using 
Abridged Anchor Primer (provided by the kit) and a reverse 
primer annealing between nucleotides 40 and 62 (5′-GAGT-
TAGTTTGGGCAGCAGATCC-3′). Whole mouse lambda 
chain was amplified by RT-PCR. cDNA was synthesized us-
ing oligo-dT, and PCR was performed with a forward primer 
1-18 (5′-ATGGCCTGGAYTTCACTT-3′) designed based on 
the sequences for leader peptides of mouse lambda-1 and 
lambda-2 variable regions17, 18 and reverse primers for mouse 
lambda-1 687-705 (5′-CTAGGAACAGTCAGCACG-3′) and 
mouse lambda 2 685-705 (5′-TTAGAGACATTCTGCAG-
GAGA-3′), based on the published antibody lambda con-
stant regions.19 The amplified DNA fragment was cloned in 
pGEM-T Easy Vector (Promega Corp.).
Construction of recombinant baculoviruses for the production of 
chimeric IgG1 and IgG2
The assembly of variable and constant heavy and light 
chains as fusion proteins is described in the “Results” sec-
tion. The DNA sequence coding for complete chimeric light 
chain was released from pGEM-T Easy vector (Promega) 
and cloned at the Bgl II site in baculovirus transfer vector 
pAcUW51 (Pharmingen, CA, USA) to obtain vector pAc-
ISU25-PIGλ. DNA sequence for complete chimeric heavy 
chains (gamma-1 and gamma-2) were then released from TA 
vector and cloned at the BamH I site in vector pAc-ISU25-
PIGλ, to obtain vectors pAc-ISU25-PIGλ/γ1 and pAc-ISU25-
PIGλ/γ2, respectively, carrying the encoding sequences for 
chimeric [mouse × pig] IgG1 and IgG2 complete antibodies. 
The inserts were sequenced seven times and no unexpected 
mutations were introduced during the cloning procedure.
Production and purification of chimeric IgG1 and IgG2
Sf 9 cells were cotransfected with vectors pAc-ISU25-
PIGλ/γ1 or pAc-ISU25-PIGλ/γ2 and BaculoGold® linearized 
baculovirus DNA (Pharmingen) by the calcium phosphate 
method, following the instructions of the manufacturer. Re-
combinant viruses produced by homologous recombina-
tion and carrying the sequences for chimeric IgG1 and IgG2 
were obtained from supernatants 4 days post-transfection, 
plaque-purified, and amplified to produce a high titer viral 
stock. Intracellular expression of chimeric immunoglobulins 
in infected cells was assessed by immunofluorescence using 
a FITC-conjugated anti-pig IgG (H+L) (KPL, MD, USA). Sf 9 
cultures at a density of 2 × 106 cells/mL were infected with 
recombinant viruses at a multiplicity of infection (m.o.i.) of 5 
and grown in serum-free medium (Sf-900 II SFM, Gibco-Invi-
trogen) at 26°C over a shaking platform. After 5 days of cul-
ture (~50% of dead cells), cultures were harvested and clar-
ified by centrifugation at 10,000g for 5 min. The virus and 
other large particles were pelleted by ultracentrifugation at 
40,000g for 30 min. The supernatants were concentrated by 
ultrafiltration using 80-mL recipients (Centricon-80, Milli-
pore Corp., MA). Samples were centrifuged at 3,000g for 2 
h, resuspended in PBS, and centrifuged again to concentrate 
100 times the antibodies in the supernatant. Alternatively, 
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recombinant antibodies were applied to Protein A-Aga-
rose packed in Econo-columns (Bio-Rad Laboratories, CA). 
Bound IgG was eluted with 0.1 M glycine buffer pH 2.5.
Characterization of chimeric IgGs by SDS-PAGE and Western 
blot analysis
Standard procedures were performed according to Har-
low and Lane.20 Chimeric IgG1 and IgG2 affinity-purified 
by Protein-A columns and controls, 500 ng of protein per 
lane, were analyzed under reducing conditions on 15% poly-
acrylamide gels stained with Coomassie Brilliant Blue R250 
(Pierce, IL, USA). Porcine serum antibodies used as positive 
controls were purified by ammonium sulfate precipitation 
and affinity-purification through protein A-agarose columns. 
Supernatant from Sf9 cells infected with a recombinant bac-
ulovirus producing an unrelated protein (Xyl-E) was used as 
negative control. Western blots were performed using HRP-
conjugated antibodies and developed by chemiluminescence 
(Lumi-Glo®, KPL) on a classic autoradiography single-emul-
sion film (Midwest Scientific, MO, USA).
Chimeric antibodies chains were identified in Western 
blot analyses by an anti-porcine IgG (KPL) and commercial 
monoclonal antibodies identified as heavy-chain specific for 
porcine IgG1 (Cat. no. MCA635; clone K139 3C8) and porcine 
IgG2 (Cat. no. MCA636; clone K68 Ig2) and specific for por-
cine Lambda chain (Cat. no. MCA633; clone K139 3E1) from 
Serotec Ltd., Oxford, UK. The three monoclonal antibodies 
have an IgG1/kappa isotype; then, a rat anti-mouse kappa 
horseradish peroxidase (HRP)-conjugated antibody (Cat. no. 
MCA1291P, Serotec Ltd.) was used as secondary antibody. A 
Western blot using glycosilated and deglycosilated porcine 
total IgG was performed to assess whether different glyco-
silation pattern in insect cells could affect the recognition of 
monoclonal anti-porcine IgG1 or IgG2. Two polyclonal IgG 
samples, purified from serum pools, were treated with N-
glycanase [Peptide-N4-(acetyl-β-glucosaminyl)-asparagine 
amidase] (PROzyme, CA). Two micrograms of treated and 
untreated IgG were run on a 10% polyacrylamide gel, and its 
Western blot was performed as described earlier.
Production of PRRS virus
PRRSV strain KY35 (NVLS 46907) was used as antigen 
throughout this work. Virus was grown in MARC-145 cells 
infected at an m.o.i. of 0.1 when cultures reached a conflu-
ence of 90-95% and harvested when the cytopathic effect 
reached 80% (~5 days p.i.). PRRSV was used either as a clar-
ified suspension (cell associated virus: CAV) or purified by 
ultracentrifugation on a 40% sucrose cushion. Peptide S4 
(SHITSYPAYFWC), a mimotope corresponding to epitope 
B on glycoprotein GP5 from PRRSV strain KY35, was pro-
duced by chemical synthesis.
PRRSV-ELISA
The ability of chimeric IgG1 and IgG2 to recognize com-
plete virus was assessed by ELISA analysis. Chimeric anti-
bodies from ultrafiltered supernatants were used as primary 
antibodies, followed by a goat anti-porcine IgG, HRP conju-
gated (KPL Inc.). Monoclonal antibody ISU25C1 was used 
as positive control, followed by a HRP-conjugated goat anti-
mouse IgG (KPL Inc.). Ultrafiltered supernatant from Xyl-E 
producing Sf9 cells was used as negative control.
Reactions were performed using standard procedures.20 
ELISA plates (Immulon 2 HB; ThermoElectron Corp., MA, 
USA) were coated with 5 μg of CAV-PRRSV or uninfected 
cells in sodium carbonate buffer, pH 9.6. Chimeric antibodies 
or control Xyl-E were detected with a HRP-conjugated anti-
porcine IgG (H+L) antibody (KPL Inc.), and monoclonal an-
tibodies were detected with an HRP-conjugated anti-mouse 
IgG (H+L) antibody (KPL Inc.), both at a dilution 1:1,000. Re-
actions were developed with ABTS (KPL Inc.), stopped with 
1% SDS and read at 410 nm. The absorbance read for PRRSV-
infected cells was compared with the absorbance read for 
MARC-145 non-infected cells. Values of optical densities 
(ODs) read at 410 nm are expressed as corrected OD, calcu-
lated as ½ [(OD Ms - OD Mc)+(OD ms - OD mc)], where Ms 
and ms are the maximum and minimum values for the sam-
ples while Mc and mc are the maximum and minimum val-
ues for the controls, respectively.
PRRSV-epitope B ELISA
A peptide-ELISA was performed to determine the ability 
of mouse × pig chimeric antibodies to recognize peptide S4 
(SHITSYPAYFWC), as described earlier.21 Reacti-Bind Ma-
leimide-Activated Plates (Pierce Biotechnology, Rockford, 
IL) were coated during 6 h with 2.5 μg of either peptide S4 or 
irrelevant peptide P7 (QRAYLELPPWPPC) in PBS at pH 6.8. 
Both peptides carry a terminal cysteine that allows binding 
to activated plates through stable thio-ether bonds at neutral 
pH. Free maleimide groups were blocked by 1-h incubation 
of 10 μg/mL cysteine-HCl in PBS at pH 6.8. After a second 
blocking step with 10% skim milk in PBS, ELISA was carried 
out following the ELISA protocol described earlier. Again, 
values of absorbance at 410 nm were expressed as corrected 
OD as described earlier.
Western blot analysis
Western blots were performed with CAV-PRRSV as well 
as sucrose-purified PRRSV. Chimeric antibodies were de-
tected with an HRPO-conjugated anti-porcine IgG (H+L) an-
tibody (KPL Inc.) while monoclonal antibody ISU25C1 was 
detected with an HRP-conjugated anti-mouse IgG (H+L) an-
tibody (KPL Inc), both at a dilution 1:1,000. Reactions were 
developed by chemiluminescence or through a precipitat-
ing substrate (TMB 1-component Membrane Peroxidase Sub-
strate; KPL Inc.).
Neutralization of PRRSV
The efficiency of chimeric antibodies on PRRSV neutral-
ization was evaluated through a fluorescent foci reduction 
assay measured 24 h p.i. A viral focus was defined as four or 
more infected cells identified by an immunofluorescence re-
action in the cell cytoplasm. PRRSV was used at a concen-
tration of 50-100 foci forming units (FFU) in a volume of 50 
μL. The percent of neutralization was obtained comparing 
the average foci number detected when ultrafiltered super-
natants with chimeric IgG1 and IgG2 were added to PRRSV 
(sample), vs. the average foci number documented when 
only RPMI medium was added (control). Ultrafiltered super-
natant containing the nonrelated protein Xyl-E and ammo-
nium sulfate-precipitated IgG, purified from a pool of normal 
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(nonimmune) sera, were used as negative controls. Monoclo-
nal antibody ISU25C1 and ammonium sulfate-precipitated 
IgG purified from a pool of hyperimmune sera were used as 
positive controls. Immunofluorescence was performed with 
monoclonal antibody SDOW17 (National Veterinary Labo-
ratory Services, NVLS, USDA, IA) that recognizes a highly 
conserved epitope on PRRSV nucleocapsid protein 22 and a 
fluorescein-conjugated anti-mouse IgG (H+L) antibody (KPL 
Inc.). Results are expressed as inhibition percentage in FFU 
as determined by the immunofluorescence assay, after the 
formula: 100 × sample FFU × (control FFU-1).
ELISA tests for assessing C1q Binding
A dot-ELISA was developed to assess the ability of chi-
meric antibodies to bind the complement component hu-
man C1q, using chimeric IgG1 and IgG2 affinity-purified 
through protein-A agarose columns followed by ultrafiltra-
tion to concentrate the purified proteins. A porcine-IgG stan-
dard (Cat. no. P100-105, Bethyl Laboratories, TX) was used 
as positive control, and a human-IgA standard (Cat. no. 
P80-102, Bethyl Laboratories, TX) was used as negative con-
trol. Two microliters of twofold dilutions (starting at 1 μg/
μL) of each antibody were dotted on nitrocellulose mem-
branes at 37°C in a humid chamber during an hour. Mem-
branes were gently washed with PBS Tween 20 (PBST) and 
blocked at 4°C overnight with 10% skim milk in PBST. Hu-
man serum (Cat. no. S-1764, Sigma, MO, USA) was used as 
source of C1q, at a 0.2% concentration in PBST with 5% skim 
milk. C1q binding to membrane-absorbed immunoglobulins 
was detected with an anti-human complement C1q goat an-
tibody (Fraction IgG) FITC-conjugated (Cat. no. 55166, ICN 
Pharmaceuticals, OH, USA) diluted 1:2,000, followed by an 
anti-FITC monoclonal antibody alkaline phosphatase-conju-
gated (Clone FL-D6, Sigma A-1812, Sigma) in a 1:30,000 di-
lution. On each step, membranes were incubated during 1 
h, followed by a 15-min and two 5-min manual washes with 
PBST. Dot-ELISA was developed with BCIP/NBT (KPL Inc.). 
Each sample was studied in duplicates, and the whole exper-
iment was repeated two independent times.
An ELISA test was performed coating 96-well microplates 
with chimeric or standard antibodies and then following the 
same procedure described for the Dot-ELISA. Immulon® 
2HB plates (ThermoElectron Corp) were sensitized overnight 
at 4°C with twofold dilutions of each antibody in 10 mM car-
bonate buffer, pH 9.2. Human serum complement was added 
at a dilution 1:250 (0.4%), anti-human complement C1q was 
used at a 1:1,000 dilution and monoclonal anti-FITC alkaline 
phosphatase-conjugated antibody was used at a 1:10,000 di-
lution. Each reagent was diluted in PBST-5% skim milk and 
incubated for 1 h at room temperature under shaking. Plates 
were manually washed six times after each step, developed 
with a soluble form of BCIP substrate (Blue-Phos Microwell 
Substrate Kit; KPL Inc.) and read at 650 nm.
Results
Cloning and expression of chimeric IgG1 and IgG2
Porcine constant lambda and gamma-1 were identical 
to the reported sequences posted at GenBank (M59322 and 
U03778, respectively). Porcine gamma-2 showed 99% identity 
with both gamma-2a (GenBank no. U03779) and gamma-2b 
 
 
 
 
 
 
 
 
 
 
 
 
(GenBank no. U03780). Paired comparison with gamma-2a 
showed nine differences between nucleotides and three amino 
acid substitutions, 15 G →S, 18 V→T and 47 T →S, while com-
parison with gamma-2b showed five differences at the nucleo-
tide level and two substitutions at the amino acid level, 7 S →
L and 18 V →T (Table 1). All these differences are located in 
the CH1 domain of the molecule. Thus, this sequence repre-
sents a mixture of those described as gamma-2a and gamma-
2b, and it was named as “Gamma2.” This sequence is avail-
able from GenBank under accession number EU479715. 
Analysis of the sequences of the variable heavy and 
light chains from hybridoma ISU25C1 indicated that the 
heavy chain is encoded by a J558.50 VH gene (Genbank no. 
AF303881), a DSP-9 D gene (Genbank no. D13199), and a JH2 
(Genbank no. V00770) gene with three aminoacid substitu-
tions to the VH gene, two in framework 1 at positions 13 (G 
→R) and 28 (T →I) and one in CDR2 at position 57 (D →G), 
but no changes in the D and JH genes (Figure 1, Support-
ing Information). Analysis of the light sequence indicated a 
lambda-1 chain using the Vλ1 gene (Genbank no. V00811) 
and Jλ1 (Genbank X58419) with an aminoacid substitution (A 
→P) at position 28 in the CDR1 (Figure 2, Supporting Infor-
mation). Based on this information, a strategy for cloning the 
mouse variable genes in frame with the pig constant genes 
was designed. 
Figure 1 (left panel) shows the flowchart and strategy used 
to clone mouse Vλ in frame with porcine constant lambda 
and mouse VH coding regions in frame with porcine constant 
gamma-1 and gamma-2. To clone the mouse lambda variable 
gene used by monoclonal antibody ISU25C1 in frame with the 
pig lambda constant genes, we took advantage of the presence 
of a VN aminoacid sequence at positions 8-9 of the constant 
region of pig lambda sequence (GTCAAC) and changed it for 
a Hpa I restriction endonuclease recognition site (GTTAAC) 
without changing the IgG pig aminoacid sequence. We incor-
porated this Hpa I sequence in the 3′ end of the reverse primer 
for the mouse lambda chain variable region, and the 5′ end of 
the forward primer for the pig lambda chain constant region. 
All mouse variable heavy antibodies end with either amino-
acids VSS or VSA. Mouse VH region used by monoclonal an-
tibody ISU25C1 was reamplified placing an Xba I restriction 
endonuclease recognition site in the 3′ of the VH gene, cor-
responding to the last two codons of the variable coding re-
gion. The VH was cloned in frame with gamma genes using 
a Nhe I restriction endonuclease recognition site in the 5′ of 
the gamma regions, restoring the original Ser-Ser aminoacids 
at the end of the JH coding region.
A restriction endonuclease recognition site for Bgl II was 
inserted 5′ to the sequence coding for the VL leader pep-
tide and 3′ to the lambda chain stop codon, while a restric-
Table 1. Constant Heavy Chain in Chimeric IgG2 Compared to 
IgG2a and IgG2b (Aminoacid Multiple Alignment)
Sequence, Author                                         Amino Acid Residue
(GenBank Accession No.) 007 015 018 047
IgG2, this paper (EU479715) S G V T
IGg2a, Kacskovics 13 (U03779) S S T S
IgG2b, Kacskovics 13 (U03780) L G T T
Val 18 in IgG2 is coded by GTG while Thr 18 in both IgG2a and 
IgG2b is coded by ACG.
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tion endonuclease recognition site for BamH I was inserted 
5′ to the sequence coding for the VH leader peptide and 3′ 
to the gamma chains stop codons, to allow cloning com-
plete lambda and gamma chains coding sequences in Bgl II 
and BamH I cloning sites at baculovirus transfer vector pAc-
UW51 (Figure 1, right panel).
Chimeric antibodies obtained from the supernatants of 
baculovirus infected-Sf9 cell cultures and purified by ul-
trafiltration reached concentrations of 30 to 100 μg/mL. 
Gamma-1 and gamma-2 chains from chimeric antibodies 
showed to be slightly lighter than heavy chains from porcine 
a Western blot (Figure 2, left panel). Monoclonal antibody 
 
 
serum but were recognized by an anti-porcine IgG (H+L) in 
K139 3C8 (anti-porcine IgG1) recognized chimeric gamma-
1 and not gamma-2 (Figure 2, middle panel), while mono-
clonal antibody K68 Ig2 did not recognize either gamma-1 
or gamma-2 (Figure 2, right panel) but did recognize heavy 
chains from purified serum IgG. This lack of recognition was 
not due to the different glycosilation pattern showed by chi-
meric gamma-2 produced in insect cells. K68 Ig2 recognized 
both glycosilated and deglycosilated porcine total IgG in a 
Western blot (Figure 3, Supporting Information). To deter-
mine the target for K68 Ig2, we tested it against IgG4, since 
this is the closest to IgG2 in sequence.13 We cloned both por-
cine IgG2 and IgG4 in Vector pGEMEX®, expressed them 
in E. coli and run them in a Western blot. It was shown that 
Figure 1. Flow chart and strategy to clone chimeric mouse × pig IgG1 and IgG2 antibodies.Left panel shows primers used to amplify the 
3′ end of variable regions and the 5′ end of constant regions, to clone in frame variable and constant regions in chimeric lambda-1 chain 
(upper left) or gamma-1 and gamma-2 chains (lower left). Right panel shows flow chart to clone complete chimeric light and heavy chains 
in baculovirus transfer vector pAc-UW51.
Figure 2. Western blot analysis of baculovirus-expressed mouse 
× pig chimeric antibodies developed with chemoluminiscense us-
ing anti-porcine IgG (H+L) (left panel), anti-porcine IgG1 (middle 
panel), and anti-porcine IgG2 (right panel).Lane 1: chimeric IgG1/
lambda; Lane 2: chimeric IgG2/lambda; Lane 3: porcine purified 
Igs (0.5 μg/sample).
Figure 3. Mouse × pig-chimeric antibodies recognize PRRSV’s 
GP5.Left panel: PAGE; Middle-left panel: Western blot developed 
with chimeric IgG1; Middle-right panel: Western blot developed 
with chimeric IgG2. Right panel: Western blot developed with 
monoclonal antibody ISU25C1. Lane 1: PRRSV-infected cells, Lane 
2: Noninfected cells, Lane 3: MW Marker (116-66.2-45-35-25 kDa), 
Lane 4: purified PRRSV. Arrow shows apparent molecular weight 
of 25 kDa
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monoclonal antibody K68 Ig2 recognized IgG4 heavy chain but 
not IgG2 heavy chain cloned and expressed in the same sys-
tem (Figure 4, Supporting Information). The main differences 
between the sequence of chimeric IgG2 and IgG4 reside on the 
CH3 domain (94% identities for aminoacids) and possibly this 
could be the area recognized by this monoclonal antibody. 
Mouse × porcine chimeric antibodies recognize the epitope in 
PRRSV described for monoclonal antibody ISU25C1
Both chimeric antibodies recognized PRRSV-infected 
MARC-145 cells by ELISA. Values shown on Table 2 (left col-
umn) correspond to a representative experiment of six inde-
pendent experiments and are expressed as the normalized 
OD between PRRSV-infected and noninfected MARC-145 
cells. Protein Xyl-E secreted by baculovirus-infected cells 
concentrated using the same methodology as for the chime-
ric antibodies was used as a negative control. Cell-culture su-
pernatant from hybridoma ISU25C1 was used as a positive 
control but was developed with an anti-mouse (H+L) per-
oxidase-conjugated antiserum as secondary antibody. Posi-
tive (hyper-immune) or negative (nonimmune) porcine sera 
could not be used in this ELISA because both showed very 
high background signals against noninfected cells (data not 
shown). In addition, both chimeric IgG1 and IgG2 antibodies 
recognized a linear epitope of glycoprotein GP5 (25 kDa), the 
same protein recognized by monoclonal antibody ISU25C1, 
 
 
 
 
 
 
in PRRSV infected MARC-145 cells as well as sucrose-puri-
fied PRRSV (Figure 3). In a peptide-ELISA format (Table 2, 
right column) mouse × porcine chimeric antibodies recog-
nized the PRRSV-GP5 mimotope represented by peptide 
S4, the same epitope recognized by monoclonal antibody 
ISU25C1.21 This peptide-ELISA was developed with peroxi-
dase-conjugated anti mouse (H+L) or anti-pig (H+L) antisera 
as secondary antibodies. Hyperimmune serum from PRRSV 
infected pigs with a neutralization titer of 256 also recog-
nized S4 in a peptide-ELISA format using the same peroxi-
dase-labeled anti-pig antiserum used with chimeric antibod-
ies. Thus, mouse × porcine chimeric antibodies recognized 
the same protein and epitope as ISU25C1. 
 
Mouse × pig chimeric IgG1 and IgG2 neutralize PRRS virus
Cell culture supernatant from hybridoma ISU25C1 in-
hibits the production of 60% of viral foci when 100 FFUs of 
PRRSV are added to MARC-145 cells.16 Supernatants from 
baculovirus infected-Sf9 cells containing chimeric IgGs, 
semipurified and concentrated by ultrafiltration at a con-
centration of 15 μg/mL, produced an inhibition in viral foci 
formation that averaged an inhibition of 56% for IgG1 and 
53% for IgG2 in three different independent experiments, us-
ing at least three wells per sample (Figure 4). Supernatants 
from baculovirus infected-Sf9 cells containing unrelated Xyl-
E protein, also semipurified by ultrafiltration, in the same 
concentration produced no reduction in FFUs. Thus, besides 
recognition of the same epitope than the original monoclo-
nal antibody ISU25C1, mouse × pig chimeric antibodies also 
neutralize PRRSV in a similar fashion as ISU25C1.
Hyperimmune Igs rendered 95% reduction in viral foci at 
a concentration of 60 μg/mL, while nonimmune Igs rendered 
no neutralization even at a concentration of 220 μg/mL.
Chimeric IgG1 and IgG2 bind human complement C1q
To test the binding capabilities of pig gamma-1 and 
gamma-2 to C1q of human complement, antibodies were 
studied by ELISA and Dot-ELISA. Complement binding 
was assessed by addition of a goat anti-human C1q FITC-
conjugated antibody followed by a peroxidase-conjugated 
anti-FITC monoclonal antibody. These experiments showed 
that both pig IgG1 and IgG2 bind human C1q component of 
complement, with IgG2 being two times more efficient than 
IgG1 (Table 3 and Figure 5, Supporting Information). Stan-
dard porcine IgG behaved in a similar manner than chime-
ric IgG2. Chimeric IgG2 showed OD values 2.4 times higher 
than chimeric IgG1, while standard porcine IgG showed OD 
values 1.8 times higher than chimeric IgG2. Similar results 
were obtained in a Dot-ELISA format (Figure 5, Supporting 
Information). 
Figure 4. PRRSV neutralization by chimeric antibodies IgG1 and 
IgG2.Results are expressed as the inhibition percentage in viral 
foci forming units detected in an immunofluorescence assay (see 
Materials and Methods).
Table 2. Chimeric Antibodies Recognize Cell-Associated (CAV)-
PRRSV in an ELISA Test and Peptide S4 (PRRSV-GP5 Mimotope) in a 
Peptide-ELISA Test
Sample    ELISAa Peptide-ELISAb
IgG1 (1.5 μg/mL)   1.132 (±0.044) 0.753 (±0.045)
IgG2 (1.5 μg/mL)   1.417 (±0.028) 0.689 (±0.039)
Xyl-E (1.5 μg/mL) –0.032 (±0.002)   ND
Hyperimmune serum    ND 1.400 (±0.109)
Negative serum    ND 0.195 (±0.019)
ISU25-C1   1.980 (±0.002) 1.150 (±0.032)
K99 –0.008 (±0.003) 0.085 (±0.006)
Values of optical densities (ODs) read at 410 nm are expressed as nor-
malized OD (±SD), calculated as ½ [(OD Ms – OD Mc) + (OD ms – OD 
mc)], where Ms and ms are the maximum and minimum values ob-
tained for the samples (a) CAV-PRRSV or (b) Peptide S4, while Mc and 
mc are the maximum and minimum values obtained for the controls 
(a) noninfected cells or (b) peptide P7. ND, not done.
Table 3. ELISA to Detect C1q Binding to Chimeric IgG1 and IgG2
Concentration                                      Standard  
 (mg/mL)        IgG1     IgG2                   Porcine IgG
0.50 0.053 (±0.025) 0.130 (±0.026) 0.232 (±0.021)
0.25 0.040 (±0.023) 0.096 (±0.007) 0.176 (±0.018)
0.12 0.029 (±0.019) 0.031 (±0.011) 0.069 (±0.008)
0.06 0.015 (±0.022) 0.002 (±0.008) 0.026 (±0.009)
ELISA to detect C1q binding to chimeric IgG1 and IgG2. Standard por-
cine IgG was used as positive control. Results are expressed as nor-
malized OD (±SD).
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Discussion
In this article, we showed that mouse × pig chimeric anti-
bodies can be expressed maintaining the binding properties 
of the mouse Fv as well as properties of the pig constant re-
gions such as complement activation.
The classification of pig IgG subtypes is still under dis-
cussion.13, 23 We produced two chimerics using the constant 
regions of pig IgG1 and IgG2. The rationale of this selec-
tion is based on the fact that at the aminoacid level IgG2a/
IgG2b and IgG4 have a 94% of identity while IgG1 and IgG3 
have a 96% of identity, compared to 87% of identity be-
tween IgG1 and IgG2a/IgG2b. This data suggest that the 
two (IgG1 and IgG2) are truly different subisotypes of pig 
immunoglobulins.
Mab K139 3C8 recognizes pig IgG1 but not IgG2 while 
Mab K68 Ig2 does not recognize IgG1 or IgG2 (Figure 2). 
Since IgG4 is the closest to IgG2 in sequence,13 we cloned 
and expressed both IgG2 and IgG4 in bacteria. This IgG4 is 
recognized in a Western blot by K68 Ig2 monoclonal anti-
body while IgG2 is not. The main differences between the se-
quences of chimeric IgG2 and IgG4 resides on the CH3 do-
main (94% identities for aminoacids) and possibly this could 
be the area recognized by this antibody.
The induction of different IgG subclasses has been corre-
lated with protective immunity in mice,24 humans,25 cattle,26 
and other species, but not in pigs. The expression of chime-
ric mouse × human antibodies has been useful for the under-
standing of the functions of the different IgG subclasses.27, 28 
The expression of chimeric mouse × pig IgG antibodies helps 
in the knowledge of the functions of pig IgGs as well as the 
characterization of these molecular defined antibodies,29 and 
it is a byproduct of this work. To determine the capabilities of 
chimeric pig IgG1 and IgG2 to activate complement using the 
classical pathway, C1q was added to the chimeric antibodies in 
an ELISA and Dot-ELISA formats (Table 3 and Figure 5, Sup-
porting Information). These experiments showed that IgG2 
binds complement up to four times better than IgG1. These re-
sults are in agreement with previous research that showed that 
IgG2 obtained from pig serum is more efficient in activating 
complement that IgG1 measured by lysis of red blood cells.30 
These authors postulated that the higher flexibility shown by 
the aminoacids present at the hinge of IgG2 and IgG4 allows 
for better activation of complement. Thus, the better activation 
of complement by IgG2/IgG4 might be due to C1q activation, 
and the expression of chimeric mouse × pig antibodies does 
not impair this property located in the CH2 domain.
ISU25C1 binds to an area of GP5 of PRRSV that we pre-
viously named epitope B and is the immunodominant neu-
tralizing epitope of PRRSV.21, 31 The Fv mouse antibody frag-
ments expressed as chimeric antibodies recognize the same 
epitope as the original mouse monoclonal antibody ISU25C1 
as demonstrated by recognition of PRRSV-infected cells in an 
ELISA format as well as the peptide S4 in a peptide-ELISA 
format (Table 2), and PRRSV-GP5 in a Western blot format 
(Figure 3). Moreover, chimeric antibodies neutralize PRRSV 
(Figure 4) similar to the parent mouse monoclonal antibody 
ISU25C1. Thus, expression of mouse Fvs in-frame with pig 
IgG antibodies does not impair the paratope of the mouse 
antibodies or the function of neutralization located in this 
fragment of the parental mouse antibody.
Neutralizing monoclonal antibodies available against 
PRRSV, including ISU25C1, have low neutralizing activ-
ity.16, 32 The VDJ gene of ISU25C1 presents two mutations 
in framework 1 and one in CDR2 compared to putative VH 
gene J558.50 and the use of D gene DSP9 read in the third 
reading frame without mutations (Figure 2, Supporting In-
formation). The low mutation rate in the complementarity 
determining regions of this antibody suggests that there is 
no affinity maturation involved in this antibody induced in 
mice by hypermutation. It seems that the presence of sug-
ars in the area around epitope B covers this epitope from 
antibodies, since a mutant depleted of glycosylation at po-
sitions 34 and 51 is more immunogenic in pigs.33 This gly-
can shielding strategy seems to be also used by HIV and 
represents an obstacle to develop neutralizing antibodies 
against HIV in mice.34 The production of next generation 
mouse hybridomas using deglycosilated PRRSV as immu-
nogen would allow for broad and more potent neutral-
ization monoclonal antibodies against PRRSV. These hy-
bridomas could be used in the future as donors of VH-VL 
genes for the construction of mouse × pig chimeric neutral-
izing antibodies against PRRSV using the vectors described 
here.
Epitope B is also the target to neutralizing antibodies in-
duced in pigs, though the area recognized by these antibod-
ies is different.21 This difference might be related to differ-
ences in the generation of antibody diversity in pigs.35, 36 It 
is now possible to produce Fvs libraries of pig antibodies.37 
The combination of this technology with the one described 
here would allow for the production and expression of 100% 
pig antibodies against PRRSV.
Here we show that chimeric mouse × pig antibodies do 
maintain the same properties that the parent domains. The 
production of recombinant antibodies as prophylactic and/
or therapeutic tools in humans has blossomed in the last 10 
years. So far, these antibodies are produced in mammalian 
cells, but different approaches to produce in other less ex-
pensive systems are under experimentation. The production 
in insect cells has shown to be quite expensive and still with 
unpredictable results. Plants seem to be systems that could 
produce high quantities at low price and expression has been 
improved in the last few years.38 Thus, chimeric antibodies 
could be used as preventive and therapeutic tools in animals 
of economic importance when the technology to produce 
these antibodies becomes more cost effective. The method 
used in these experiments would be a universal method for 
construction of mouse × pig chimeric antibodies. This strat-
egy could be used alone or accompanying other strategies 
as vaccination to provide instant immunity in the face of an 
outbreak and before the establishment of effective adaptive 
immune response of the pig.
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